Related Experiment Videos
New approaches to antibody therapy
1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Abstract:
Antibody-based therapy of human cancers has led to several remarkable outcomes, particularly in the therapy of breast cancer and lymphoma. Many solid tumors have proven less responsive, due in part to difficulties in the tumor-selective delivery of antibodies and potential cytolytic effectors. However, antibodies that directly perturb signaling mechanisms in cells derived from epithelial malignancies have shown benefit; examples include antibodies directed against the extracellular domains of HER2/neu and epidermal growth factor receptor. A long-term goal of immunotherapy has been to induce anti-tumor inflammatory responses that can directly cause tumor regression or induce adaptive responses against tumor-related antigens. This review focuses on the use of antibodies to provide a means for initiating anti-tumor immune responses, and on the use of antibodies as delivery vehicles of radionuclides.
Insights
Antibody therapies show promise for breast cancer and lymphoma. This review explores using antibodies to initiate anti-tumor immune responses and deliver cancer-targeting radionuclides for solid tumors.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Therapeutics
Background:
- Antibody-based therapies have achieved success in treating breast cancer and lymphoma.
- Solid tumors present challenges for antibody therapy due to delivery and effector function limitations.
- Targeting signaling pathways via antibodies against HER2/neu and EGFR has benefited epithelial malignancies.
Purpose of the Study:
- To review the role of antibodies in initiating anti-tumor immune responses.
- To discuss the application of antibodies as delivery vehicles for radionuclides in cancer treatment.
Main Methods:
- Literature review of antibody-based cancer therapies.
- Analysis of antibodies targeting signaling pathways and immune responses.
- Evaluation of antibody-mediated radionuclide delivery systems.
Main Results:
- Antibodies targeting extracellular domains like HER2/neu and EGFR show efficacy in epithelial cancers.
- Inducing anti-tumor inflammatory responses is a key goal for immunotherapy.
- Antibodies can be engineered to deliver cytotoxic payloads like radionuclides.
Conclusions:
- Antibody therapy is a powerful tool in oncology, with ongoing advancements for solid tumors.
- Future directions include enhancing immune responses and targeted delivery of therapeutic agents.
- Antibodies offer versatile strategies for cancer treatment, from direct signaling modulation to targeted payload delivery.